Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
HOME > ORGANIZATION
ORGANIZATION
- EFPIA Japan Chief Urges Govt to Maintain Support for Innovation
November 2, 2017
- Boehringer’s Thorsten Poehl Named EFPIA Japan Vice Chairman
October 31, 2017
- Global Pharma CEOs Prod Japan to Keep Pro-Innovation Policy, Sound Alarm on Proposed PMP Review
October 31, 2017
- PhRMA, EFPIA Upping Lobbying Campaigns amid Drug Pricing Overhaul
October 30, 2017
- JPMA Reprimands Bayer over Side Effect Reporting Violation, Chides “Inappropriate” Promotion
October 20, 2017
- Securities Analysts Rank Shionogi No. 1 among Drug Markers for “Excellence in Disclosure”
October 17, 2017
- JMA President Yokokura Heads WMA
October 17, 2017
- OTC Switching of Emergency Contraceptive Levonorgestrel Will Be Difficult Under Current System: JPA
October 16, 2017
- Taskforce Discussing Info-Sharing Between Drug Makers in Non-Competitive Fields: JPMA R&D Head
October 12, 2017
- Generic Use Rate at 67.8% in April-June: JGA
September 29, 2017
- Biologics Training Center to Start Human Resources Development in Biologics Field Next April
September 20, 2017
- Industry Wants Continued Dialogue to Keep Price Maintenance Premium in Place: Janssen Japan Chief
September 13, 2017
- Daiichi Sankyo’s Hirano to Replace Kamoya as Chuikyo Pharma Rep
September 11, 2017
- Plasma Fraction Products Should Remain in List of Essential Drugs: Blood Products Association Exec
September 11, 2017
- Introduce Permanent Price Maintenance Scheme, Don’t Rush on CEA Debate: UA Zensen
September 7, 2017
- JMA’s Imamura Questions Distribution Coefficient in Cost Calculation Formula
September 5, 2017
- LINK-J Expanding Free Consultation Service for Academic Researchers
August 31, 2017
- Cancer Advocate Warns of Lack of Patient Involvement in CEA Debates
August 30, 2017
- Impact of Drug Price Revisions on Company Management Unclear: JMA Think Tank
August 22, 2017
- JPWA Member Firms Suffer Record 3.5% Sales Fall on Drop-Off in Demand for Hepatitis C Meds
August 16, 2017
ページ
With Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) hogging the headlines for its biggest-ever price tag in Japan, many continue to perceive high-price medicines as the main culprit of strained health finances, contending that they are driving up drug spending. But, is…
The workforce in the Japanese pharmaceutical sector is getting leaner and leaner, with the latest securities reports filed by 27 drug makers showing a 1.3% fall in their headcounts in FY2018, or 888 employees. The downtrend has been continuing since…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…